Cingulate Therapeutics (CTx) is a privately held biopharma company developing new products for the treatment of Neurobiological Disorders. Currently, CTx is developing two products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cingulate-therapeutics” connections=”true” suffix=””]
Sep 2014, Catalent Pharma Solutions signed an exclusive development and licensing agreement with Cingulate Therapeutics, to support the development of a series of new prescription pharmaceutical products for the treatment of ADHD using Catalents OSDrC OptiDose drug delivery platform.
In July 2018, Cingulate Therapeutics LLC announced a $7.5Mn equity investment from Werth Family Investment Associates. The capital will advance lead products into further clinical trials.